Lenalidomide in treating AIDS-related Kaposi's sarcoma

AIDS

Volumn 25, Issue 6, 2011, Pages 878-880

  Martinez, Valérie ^a   Tateo, Mariagrazia ^a   Castilla, Marie Angèle ^b   Melica, Giovanna ^c   Kirstetter, Myriam ^d   Boué, François ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; INTERFERON; LENALIDOMIDE; VINDESINE;

ADULT; ASTHENIA; CASE REPORT; CD4 LYMPHOCYTE COUNT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN TISSUE; KAPOSI SARCOMA; LETTER; LYMPHEDEMA; MALE; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; HIV-1; HUMANS; SARCOMA, KAPOSI; SKIN NEOPLASMS; THALIDOMIDE;

EID: 79953734340     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328344c145     Document Type: Letter

References (10)

1. Martellotta F, Berretta M, Vaccher E, Schioppa O, Zanet E, Tirelli U. AIDS-related Kaposi's sarcoma: state of the art and therapeutic strategies. Curr HIV Res 2009; 7:634-638.
2. Cattelan AM, Trevenzoli M, Aversa SM. Recent advances in the treatment of AIDS-related Kaposi's sarcoma. Am J Clin Dermatol 2002; 3:451-462. (Pubitemid 35007063)
3. Hengge UR, Ruzicka T, Tyring SK, Stuschke M, Roggendorf M, Schwartz RA, et al. Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 1: Epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect Dis 2002; 2:281-292.
4. Nasti G, Martellotta F, Berretta M, Mena M, Fasan M, Di Perri G, et al. Impact of highly active antiretroviral therapy on the presenting features and outcome of patients with acquired immunodeficiency syndrome-related Kaposi sarcoma. Cancer 2003; 98:2440-2446. (Pubitemid 37466659)
5. Bartlett JB, Tozer A, Stirling D, Zeldis JB. Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide. Br J Cancer 2005; 93:613-619. (Pubitemid 41486449)
6. Crane E, List A. Lenalidomide: an immunomodulatory drug. Future Oncol 2005; 1:575-583.
7. Bibas M, Grisetti S, Alba L, Picchi G, Del Nonno F, Antinori A. Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone. J Clin Oncol 2010; 28:e704-e708.
8. Blum S, Cavassini M, Lambert JF, Fayet A, Schapira M, Jotterand M. Treatment of 5q-syndrome with lenalidomide in an HIV-positive patient under cART. Ann Hematol 2010; 89:425-426.
9. Little RF, Wyvill KM, Pluda JM, Welles L, Marshall V, Figg WD, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 2000; 18:2593-2602. (Pubitemid 30432526)
10. Ben ML, Fardet L, Mebazaa A, Thervet E, Biet I, Kerob D, et al. A retrospective analysis of thalidomide therapy in non- HIV-related Kaposi's sarcoma. Dermatology 2007; 215:202-205. (Pubitemid 47378985)